Feb 08, 2024 / 01:00PM GMT
Operator
Hello, ladies and gentlemen, thank you for standing by, and welcome to Adverums webcast to discuss preliminary efficacy and safety data from the ongoing LUNA clinical trial. (Operator Instructions) As a reminder, today's call is being recorded.
It is now my pleasure to turn the floor over to Mike Zanoni, Adverum's Head of Investor Relations, who will make introductory comments.
Mike Zanoni Adverum Biotechnologies Inc-Head of IR
Thank you, operator. Good morning, and welcome, everyone to Adverum recently issued a press release providing the details of the company's preliminary efficacy and safety results from the ongoing within a clinical trial. The press release is available in the Investor Relations section of the company's website at investors.adverum.com.
Today's call will be led by Dr. Laurent Fischer, President and Chief Executive Officer, who will be joined by Dr. Star Seyedkazemi Chief Development Officer; Peter Soparkar, Chief Operating Officer; and Linda Rubinstein, Chief Financial Officer.
In addition, it is our
Adverum Biotechnologies Inc To discuss the preliminary safety and efficacy data Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers